LDS/Medical Tests/Friedreich Ataxia, Frataxin, Quantitative, Blood

Friedreich Ataxia, Frataxin, Quantitative, Blood

Friedreich’s ataxia (FRDA) is an autosomal recessive disorder that affects children and young adults with symptoms appearing before 25 years of age. Disease is caused by homozygous guanine-adenine-adenine trinucleotide (GAA) repeat expansion that causes deficiency of frataxin, a small nuclear genome-encoded mitochondrial protein. There is a clear correlation between size of the expanded repeat and severity of the phenotype. Frataxin is a mitochondrial protein that plays a role in iron homeostasis. Deficiency of frataxin results in mitochondrial iron accumulation, defects in specific mitochondrial enzymes, enhanced sensitivity to oxidative stress, and eventually free-radical mediated mitochondrial damage, axonal degeneration cell death. Therefore, FRDA is considered a new nuclear encoded mitochondrial disease.

Friedreich’s ataxia is a slowly progressive neurodegenerative disorder affecting 1in 50,000 individuals mainly in the Caucasian population. The incidence is much lower in Asians and African ancestries. Most common syndromes associated with disease are ataxia, loss of deeptendon reflexes, muscle weakness (atrophy) often associated with scoliosis, foot deformities, cardiomyopathy and diabetes mellitus in less cases. Screening patients for mutation X25 resulted in identification of a trinucleotide repeat expansion (GAA) within the first intron of Frataxing gene located in the chromosome 9q13. Normal alleles contain between 5-33 repeats, whereas expanded alleles contain 120-1700 repeats which is characteristic of this disease. The repeats >34 results in permutation. The disease or mutation is transmitted maternally. Both genes/alleles must be affected (homozygous) to develop disease. Heterozygous where only one gene is affected will result in carrier phenotype, but will not develop disease. Molecular testing for expansion of GAA triple nucleotide repeat behind 60 repeats would confirm the diagnosis.

The diagnosis of FRDA is usually by genetic testing to detect the presence of the GAA expansion; however, testing for the triplet repeat expansion will miss those patients with point mutations or deletions. In addition, a molecular-based analysis is not able to effectively monitor treatment and disease management. Therefore, a immunoassay that measuring concentration of protein frataxin is suitable for both diagnosis as well as treatment monitoring in individuals with FRDA.

  • As an aid in diagnosis of Friedreich’s ataxia
  • Disease management and therapy monitoring
Normal results (> or =15 ng/mL for pediatric and > or =21 ng/mL for adult patients) in properly submitted specimens are not consistent with Friedreich ataxia.

Pediatric (<18 years) normal frataxin: > or =15 ng/mL Adults (> or =18 years) normal frataxin: > or =21 ng/mL

Immunoassay, ELISA.

Serum or plasma (SST, EDTA tubes). 

Stability

  • Ambient: 3-7 days
  • Refrigerated: 7-14 days
Frataxin mutation analysis, CT or CATscan (a sophisticated x-ray technique for imaging the brain or spinal cord), an MRI (magnetic resonance imaging of body tissues, including the brain and spinal cord), and EMG (electromyography, a test that records the electrical activity of muscles and nerves), Creatinine Kinase, Comprehensive metabolic panel, CBC.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Neurol Neurosurg Psychiatry. 2014 Sep;85(9):994-1002.
  • Neurol Sci. 2011 Apr;32(2):327-30. doi: 10.1007/s10072-010-0326-1.
  • J Neuropathol Exp Neurol. 2013 Feb;72(2):78-90. [PMID: 23334592]
  • World J Cardiol. 2019 Jan 26;11(1):1-12. [PMID: 30705738]
  • Biochem J. 2013 Aug 1;453(3):321-36. [PMID: 23849057]
  • J Neurol Sci. 2011 Apr 15;303(1-2):1-12. [PMID: 21315377]
  • Pediatr Neurol. 2003 May;28(5):335-41. [PMID: 12878293]
  • Int J Mol Med. 2001 Jun;7(6):581-9. [PMID: 11351269]
  • Hum Genet. 2000 Jan;106(1):86-92. [PMID: 10982187]